Microfluidic manufacture of peptide nanofibers for nose-to-brain treatment of brain tumours

Karim Osouli Bostanabad; Momchil Terziev; Bryan J Anaya; Katerina Lalatsa

Microfluidic manufacture of peptide nanofibers for nose-to-brain treatment of brain tumours

Karim Osouli Bostanabad, Momchil Terziev, Bryan J Anaya, Katerina Lalatsa

Research output: Contribution to conference › Poster › peer-review

Abstract

Glioblastoma multiforme (GBM) patients have a median survival of 15 months after surgery, radiotherapy and temozolomide treatment. Gonadotrophin releasing hormone (GnRH) are overexpressed in GBM patients, but GnRH is unable to cross the blood-brain barrier and is enzymatically unstable with a half-life of 3 minutes. We have shown that GnRH amphiphiles (TPGnRH) assemble into stable nanofibers that can bind GnRH GPCR and elicit an antiproliferative response at low micromolar concentrations causing G2/M phase arrest, while being able to cross the blood-brain barrier and target loaded cytotoxics to GBM cells. Solvent evaporation batch processes were used in manufacture of these peptide nanomedicines. Here, we aim to assess the continuous microfluidic manufacture of these nanomedicines towards achieving a nose-to-brain non-invasive therapy for GBM.

Original language	English
Publication status	Published - 8 Jul 2024
Event	Controlled Release Society Annual Meeting and Exposition - Bologna Congressi, Bologna, Italy Duration: 8 Jul 2024 → 12 Jul 2024 https://2024crsannualmeeting.eventscribe.net/

Conference

Conference	Controlled Release Society Annual Meeting and Exposition
Country/Territory	Italy
City	Bologna
Period	8/07/24 → 12/07/24
Internet address	https://2024crsannualmeeting.eventscribe.net/

Keywords

nanofibers
brain delivery
nose-to-brain delivery
microfluidics
peptide amphphiles
paclitaxel

Cite this

@conference{31006f0a513f4b3b8f69daab8398b1ec,

title = "Microfluidic manufacture of peptide nanofibers for nose-to-brain treatment of brain tumours",

abstract = "Glioblastoma multiforme (GBM) patients have a median survival of 15 months after surgery, radiotherapy and temozolomide treatment. Gonadotrophin releasing hormone (GnRH) are overexpressed in GBM patients, but GnRH is unable to cross the blood-brain barrier and is enzymatically unstable with a half-life of 3 minutes. We have shown that GnRH amphiphiles (TPGnRH) assemble into stable nanofibers that can bind GnRH GPCR and elicit an antiproliferative response at low micromolar concentrations causing G2/M phase arrest, while being able to cross the blood-brain barrier and target loaded cytotoxics to GBM cells. Solvent evaporation batch processes were used in manufacture of these peptide nanomedicines. Here, we aim to assess the continuous microfluidic manufacture of these nanomedicines towards achieving a nose-to-brain non-invasive therapy for GBM.",

keywords = "nanofibers, brain delivery, nose-to-brain delivery, microfluidics, peptide amphphiles, paclitaxel",

author = "{Osouli Bostanabad}, Karim and Momchil Terziev and Anaya, {Bryan J} and Katerina Lalatsa",

year = "2024",

month = jul,

day = "8",

language = "English",

note = "Controlled Release Society Annual Meeting and Exposition ; Conference date: 08-07-2024 Through 12-07-2024",

url = "https://2024crsannualmeeting.eventscribe.net/",

}

TY - CONF

T1 - Microfluidic manufacture of peptide nanofibers for nose-to-brain treatment of brain tumours

AU - Osouli Bostanabad, Karim

AU - Terziev, Momchil

AU - Anaya, Bryan J

AU - Lalatsa, Katerina

PY - 2024/7/8

Y1 - 2024/7/8

N2 - Glioblastoma multiforme (GBM) patients have a median survival of 15 months after surgery, radiotherapy and temozolomide treatment. Gonadotrophin releasing hormone (GnRH) are overexpressed in GBM patients, but GnRH is unable to cross the blood-brain barrier and is enzymatically unstable with a half-life of 3 minutes. We have shown that GnRH amphiphiles (TPGnRH) assemble into stable nanofibers that can bind GnRH GPCR and elicit an antiproliferative response at low micromolar concentrations causing G2/M phase arrest, while being able to cross the blood-brain barrier and target loaded cytotoxics to GBM cells. Solvent evaporation batch processes were used in manufacture of these peptide nanomedicines. Here, we aim to assess the continuous microfluidic manufacture of these nanomedicines towards achieving a nose-to-brain non-invasive therapy for GBM.

AB - Glioblastoma multiforme (GBM) patients have a median survival of 15 months after surgery, radiotherapy and temozolomide treatment. Gonadotrophin releasing hormone (GnRH) are overexpressed in GBM patients, but GnRH is unable to cross the blood-brain barrier and is enzymatically unstable with a half-life of 3 minutes. We have shown that GnRH amphiphiles (TPGnRH) assemble into stable nanofibers that can bind GnRH GPCR and elicit an antiproliferative response at low micromolar concentrations causing G2/M phase arrest, while being able to cross the blood-brain barrier and target loaded cytotoxics to GBM cells. Solvent evaporation batch processes were used in manufacture of these peptide nanomedicines. Here, we aim to assess the continuous microfluidic manufacture of these nanomedicines towards achieving a nose-to-brain non-invasive therapy for GBM.

KW - nanofibers

KW - brain delivery

KW - nose-to-brain delivery

KW - microfluidics

KW - peptide amphphiles

KW - paclitaxel

M3 - Poster

T2 - Controlled Release Society Annual Meeting and Exposition

Y2 - 8 July 2024 through 12 July 2024

ER -

Microfluidic manufacture of peptide nanofibers for nose-to-brain treatment of brain tumours

Abstract

Conference

Keywords

Fingerprint

Cite this